Pyxis Oncology (PYXS) Revenue & Revenue Breakdown
Pyxis Oncology Revenue Highlights
Pyxis Oncology Revenue by Period
Pyxis Oncology Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | - |
Pyxis Oncology generated - in revenue during NA 2023, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Pyxis Oncology Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | -100.00% |
| 2024-03-31 | $16.15M | 372.11% |
| 2023-12-31 | $3.42M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | - |
Pyxis Oncology generated - in revenue during Q2 2024, up -100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Pyxis Oncology Revenue Breakdown
Pyxis Oncology Revenue Breakdown by Product
Quarterly Revenue by Product
| Product/Service | Jun 24 | Mar 24 |
|---|---|---|
| Royalty | $8.15M | $8.15M |
Pyxis Oncology's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: Royalty (100.00%).
Pyxis Oncology Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| HOOK | HOOKIPA Pharma | $20.13M | - |
| MREO | Mereo BioPharma Group | $10.00M | - |
| CRVS | Corvus Pharmaceuticals | - | - |
| XFOR | X4 Pharmaceuticals | - | $563.00K |
| CYTO | Altamira Therapeutics | - | $52.73K |
| PDSB | PDS Bio | - | - |
| ZURA | Zura Bio | - | - |
| INZY | Inozyme Pharma | - | - |
| ELEV | Elevation Oncology | - | - |
| TERN | Terns Pharmaceuticals | - | - |
| PYXS | Pyxis Oncology | - | - |
| ZVSA | ZyVersa Therapeutics | - | - |
| OCEA | Ocean Biomedical | - | - |
| EFTR | eFFECTOR Therapeutics | - | - |
PYXS Revenue FAQ
What is Pyxis Oncology’s yearly revenue?
Pyxis Oncology's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. PYXS's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is Pyxis Oncology’s quarterly revenue?
Pyxis Oncology's quarterly revenue for Q2 2024 was $0, a -100.00% decrease from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $16.15M, a 372.11% increase from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). PYXS's quarterly revenue for Q4 2023 was $3.42M, a 100.00% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022).
What is Pyxis Oncology’s revenue growth rate?
Pyxis Oncology's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.